Publication | Open Access

Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial

Acute Hepatitis CHepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitisVirologyChronic Viral InfectionAntiviral DrugMedicineEpidemiology